In several phase 3 clinical trials, ICI monotherapy (MONO) has shown outstanding efficacy compared to chemotherapy in patients with NSCLC and PD-L1 TPS ≥ 50% and has been established as a standard first-line treatment option for such patients (5, 6). The gene discussed is CD274; the disease is non-small cell lung carcinoma.